← Leaderboards
George K Michalopoulos
University Of Pittsburgh At Pittsburgh
$12,892,897
Attributed
$13,364,835
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $632.4K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$13,364,835 · 8
By mechanism
R01$8,596,803 · 3
U01$3,012,110 · 1
P01$1,152,374 · 1
R37$577,548 · 1
R13$26,000 · 1
P41$0 · 1
Top collaborators
- Bharat Bhushan2 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Kari N Nejak-Bowen$7,645,432
- Donghun Shin$7,694,142
- Anthony J Demetris$3,529,479
- Bharat Bhushan$1,659,582
- Michael D Thompson$883,847
Others in their field
Top investigators on “Liver Regeneration”
- Robert H Squires · Children'S Hosp Pittsburgh/Upmc Hlth Sys$16,267,601
- Anna Mae Elizabeth Diehl · Johns Hopkins University$15,977,830
- Satdarshan Singh Monga · University Of Hawaii At Manoa$13,878,099
- William M Lee · University Of Texas Sw Med Ctr/Dallas$13,754,305
- Wolfram Goessling · Brigham And Women'S Hospital$12,131,857
- Mark A Kay · Stanford University$11,954,407
Research focus
Liver RegenerationLiverHepatocyteSignal TransductionReceptorDesignTranscription FactorPartial HepatectomyTissuesPathway InteractionsEgf GeneNatural RegenerationGene ExpressionEpidermal Growth Factor ReceptorProteinsGrowthLiver NeoplasmsHepaticMeetingsRegenerativeMitogensMaleHuman SubjectMalignant Neoplasm Of Liver
Grant awards (42)
Inhibition of EGF Receptor Prevents and Reverses Non-Alcoholic Fatty Liver Disease$462,307
R01 · FY2024 · DK · contact PI
Inhibition of EGF Receptor Prevents and Reverses Non-Alcoholic Fatty Liver Disease$481,570
R01 · FY2023 · DK · contact PI
Inhibition of EGF Receptor Prevents and Reverses Non-Alcoholic Fatty Liver Disease$475,260
R01 · FY2022 · DK · contact PI
Inhibition of EGF Receptor Prevents and Reverses Non-Alcoholic Fatty Liver Disease$473,996
R01 · FY2021 · DK · contact PI
Mechanisms of AT expression and hepatocyte hyper- proliferation in AT deficiency$294,587
P01 · FY2015 · DK · contact PI
Mechanisms of AT expression and hepatocyte hyper- proliferation in AT deficiency$297,888
P01 · FY2014 · DK · contact PI
HGF and Signaling Pathways in Hepatic Tissue Assembly$285,392
R01 · FY2014 · CA · contact PI
FASEB SRC on Liver Biology: Fundamental Mechanisms and Translational Applications$26,000
R13 · FY2014 · DK · contact PI
Mechanisms of AT expression and hepatocyte hyper- proliferation in AT deficiency$289,321
P01 · FY2013 · DK · contact PI
HGF and Signaling Pathways in Hepatic Tissue Assembly$276,565
R01 · FY2013 · CA · contact PI
HGF and Signaling Pathways in Hepatic Tissue Assembly$294,218
R01 · FY2012 · CA · contact PI
Mechanisms of AT expression and hepatocyte hyper- proliferation in AT deficiency$270,578
P01 · FY2012 · DK · contact PI
HGF in Liver Development, Regeneration and Neoplasia$319,227
R01 · FY2011 · CA · contact PI
HGF and Signaling Pathways in Hepatic Tissue Assembly$294,218
R01 · FY2011 · CA · contact PI
HGF in Liver Development, Regeneration and Neoplasia$329,101
R01 · FY2010 · CA · contact PI
HGF and Signaling Pathways in Hepatic Tissue Assembly$303,317
R01 · FY2010 · CA · contact PI
HGF in Liver Development, Regeneration and Neoplasia$329,101
R01 · FY2009 · CA · contact PI
HGF in Liver Development, Regeneration and Neoplasia$329,101
R01 · FY2008 · CA · contact PI
HGF and Signaling Pathways in Hepatic Tissue Assembly$282,995
R01 · FY2008 · CA · contact PI
HGF in Liver Development, Regeneration and Neoplasia$329,101
R01 · FY2007 · CA · contact PI
HGF and Signaling Pathways in Hepatic Tissue Assembly$282,995
R01 · FY2007 · CA · contact PI
HGF in Liver Development,Regeneration and Neoplasia$317,454
R01 · FY2006 · CA · contact PI
HGF and Signaling Pathways in Hepatic Tissue Assembly$291,447
R01 · FY2006 · CA · contact PI
HGF in Liver Development,Regeneration and Neoplasia$325,094
R01 · FY2005 · CA
HGF and Signaling Pathways in Hepatic Tissue Assembly$298,460
R01 · FY2005 · CA
MOLECULAR RECLASSIFICATION OF PROSTATIC CANCER$677,203
U01 · FY2004 · CA
HGF in Liver Development,Regeneration and Neoplasia$325,623
R01 · FY2004 · CA
HGF and Signaling Pathways in Hepatic Tissue Assembly$298,701
R01 · FY2004 · CA
MOLECULAR RECLASSIFICATION OF PROSTATIC CANCER$659,364
U01 · FY2003 · CA
HGF in Liver Development,Regeneration and Neoplasia$326,681
R01 · FY2003 · CA
MOLECULAR RECLASSIFICATION OF PROSTATIC CANCER$642,453
U01 · FY2002 · CA
HGF in Liver Development,Regeneration and Neoplasia$327,739
R01 · FY2002 · CA
MOLECULAR RECLASSIFICATION OF PROSTATIC CANCER$99,862
U01 · FY2002 · CA
HEPATOCYTE GROWTH FACTOR$0
P41 · FY2002 · RR
HEPATOCYTE GROWTH FACTOR$0
P41 · FY2002 · RR
MOLECULAR RECLASSIFICATION OF PROSTATIC CANCER$624,909
U01 · FY2001 · CA
HGF AND HEPATOCYTES IN NEOPLASIA AND LIVER FAILURE$292,161
R37 · FY2001 · CA
HGF IN LIVER REGENERATION, DIFFERENTIATION AND NEOPLASIA$271,729
R01 · FY2001 · CA
HEPATOCYTE GROWTH FACTOR$0
P41 · FY2001 · RR
MOLECULAR RECLASSIFICATION OF PROSTATIC CANCER$308,319
U01 · FY2000 · CA
HGF AND HEPATOCYTES IN NEOPLASIA AND LIVER FAILURE$285,387
R37 · FY2000 · CA
HGF IN LIVER REGENERATION, DIFFERENTIATION AND NEOPLASIA$265,411
R01 · FY2000 · CA